Patients treated with nivolumab had a significantly higher objective response rate than those treated with ICC (31.7% versus 10.6%, respectively), according to the first analysis of the data from patients with unresectable stage IIIC or IV metastatic melanoma, who had either progressed after anti-CTLA-4 plus BRAF inhibitor treatment (if BRAF V600 mutant melanoma) or who had failed prior anti-CTLA-4 treatment (if BRAF WT melanoma) [62]. The gene discussed is CTLA4; the disease is metastatic melanoma.